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erate hemophilia (p= 0.01), HIV (p< 0.01), HCV (p= 0.02), and factor usage (p= 0.02) 
were significantly associated with ABF. Fewer variables had a significant associa-
tion with ABF for children compared to adults, including prophylaxis (p< 0.01) and 
factor usage (p= 0.01). ConClusions: Variables associated with ABF include socio-
demographics, clinical characteristics and factor usage. The preliminary results 
reinforce the importance of optimizing treatment for individual differences. Future 
studies should investigate how variations in bleeding outcomes and treatment are 
associated with healthcare costs.
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objeCtives: A key objective of treating type 2 diabetes mellitus (TD2M) is main-
taining glycaemic control, (glycated haemoglobin-HbA1c) with targets set between 
6.5%-7.5%. Doctors frequently fail to intensify treatment in uncontrolled patients 
and a study was designed to assess the long term clinical effects of this inertia. The 
study involved Classification and Regression Tree (CART) analyses to evaluate the 
timepoint that intensification should occur to gain glycaemic control. Methods: 
Incident T2DM patients were identified in the UK CPRD database between 1 January 
2000-31 August 2014 and followed for 5 years. Patients initiated on metformin 
monotherapy and did not achieved HbA1c< 7% after 90 days. CART was applied, 
with Hba1c level as the dependent variable and three explanatory effects: time to 
intensification class (TTIc), Year and Year by TTIc interaction. For each iteration TTIc 
was assigned per subject (i.e. those patients with TTI before or after TTI cut-point). 
The goodness of fit, the Akaike Information Criteria (AIC), was obtained for the 
model and the optimal cut point was the one resulting in the lowest AIC value. This 
created two classes of subjects, rapid and delayed TTI, whose HbA1c values were 
compared Results: The model identified that the optimal intensification time 
was ≤ 244 days post the first HbA1c≥ 7% (rapid TTI). 50.7% of patients with rapid TTI 
achieved HbA1c target< 7%, compared to only 14.0% in delayed TTI, despite rapid 
patients starting with higher average HbA1c levels (8.65%) than delayed patients 
(7.85%). The effects of rapid intensification caused immediate and maintained 
reduction in glucose levels, not observed in the delayed group. ConClusions: 
CART analysis identified the optimal timing for treatment intensification post loss 
of glycaemic control as ≤ 244 days. This analytical method could be used in future 
database studies to aid in group definition by treatment exposure and provide valu-
able clinical information for physicians.
PRM2
HOw TO CONDUCT ECONOMIC EVAlUATIONS Of NEw TREATMENTS fOR 
ADVANCED CANCER wHEN OVERAll SURVIVAl DATA ARE NOT AVAIlAblE? 
RESUlTS fROM A SySTEMATIC lITERATURE REVIEw
Beauchemin C1, Lapierre M1, Letarte N1, Yelle L2, Lachaine J1
1University of Montreal, Montreal, QC, Canada, 2Centre Hospitalier de l’Université de Montréal – 
Hôpital Notre-Dame, Montreal, QC, Canada
objeCtives: Use of surrogate endpoints like progression-free survival (PFS) and 
time to progression (TTP) instead of overall survival (OS) in clinical trials for 
advanced cancer remains challenging from a health economic standpoint. This 
study assessed the use of surrogate endpoints in economic evaluations of anticancer 
drugs and methodological approaches adopted when reliable OS data are unavail-
able. Methods: A systematic literature review was conducted to identify economic 
evaluations of treatments for advanced cancer published between January 2003 
and October 2013. Cost-effectiveness and cost-utility analyses expressed in terms 
of cost per life-year gained and cost per quality-adjusted life-year using a surrogate 
endpoint as an outcome measure were eligible. Characteristics of selected stud-
ies were extracted and comprised: population, treatment of interest, comparator, 
line-of-treatment, study perspective, and time horizon. Use of surrogate endpoints 
and methods adopted when OS data were lacking were analyzed. Two reviewers 
independently selected studies and extracted data. Results: In total, 7,219 stud-
ies were identified and 100 fulfilled the eligibility criteria. Most included studies 
assessed the cost-effectiveness of a biological therapy (65%) in the first-line setting 
(56%) and in the context of advanced non-small cell lung cancer (24%) or advanced 
breast cancer (22%). Surrogate endpoints mostly used were PFS and TTP, account-
ing for 92% of included studies. OS data were unavailable for analysis in nearly 
25% of economic evaluations. In the absence of OS data, studies most commonly 
assumed an equal risk of death for all treatment groups. Other methods included 
use of indirect comparison based on numerous assumptions, use of a surrogate 
endpoint as a proxy for OS, consultation with clinical experts, and use of OS data 
associated with different patient populations or treatment-line. ConClusions: 
Although several approaches are used, there is no consensus method to estimate 
the cost-effectiveness of new anticancer drugs in the absence of reliable OS data.
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Of CONTRAST MEDIA IN INPATIENT INTERVENTIONAl CARDIOVASCUlAR 
PROCEDURES
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(MM). Methods: Telephone interviews lasting approximately 1 hour were conducted 
with two HTA experts from each country, based on an interview guide. Interviews were 
recorded and common themes identified from assessment of the narrative. Results: 
The French advisors considered that the cost savings realized through informal care 
compared with formal caregiving are neglected, and that data on informal caregiver 
burden should be incorporated into cost-effectiveness models where available. The 
German advisors suggested that caregiver burden may be recognized in HTA if it can 
be related to patient benefit. Discussions in this area are increasing but changes to 
the acceptability of caregiver burden data was mostly likely to occur elsewhere in the 
healthcare system (i.e., outside of the benefit assessment process). Advisors in the US 
reported that payers’ views of caregiver burden are changing and that this information 
should be considered as more patients involve their caregivers in decision-making, or 
caregivers make the decisions (for some groups of patients). ConClusions: Informal 
caregiver burden data are not currently considered important in HTA in Europe or 
the US, although there are suggestions that this may change. Even where such data 
have been included in HTA submissions, they have not generally been a driver of 
HTA decision-making.
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objeCtives: Data from real-world European settings describing treatment patterns 
and outcomes in relapsed/refractory multiple myeloma (RRMM) are limited. This 
study helps address this knowledge gap using a brief physician survey. Methods: 
Sixty-one physicians treating RRMM were surveyed (November 2014) in France 
(n= 21), Germany (n= 20), and the United Kingdom (UK) (n= 20). The survey collected 
physicians’ opinions on typical treatment patterns and outcomes of RRMM patients 
in the relapse/refractory setting (following disease progression during/after first-
line therapy). Analyses were descriptive. Results: Sixty percent of physicians in 
France and the UK were haematologists, versus 10% in Germany (where 80% were 
onco-haematologists). The proportion of patients with high-risk disease based on 
ISS stage and cytogenetics was 18%-24% across countries. Bortezomib/thalidomide/
dexamethasone was the most common induction regimen (42%) for stem cell trans-
plant (SCT)-eligible patients in France, but was unused in Germany and less com-
monly prescribed in the UK (17%); bortezomib/cyclophosphamide/dexamethasone 
was the reported induction therapy for 28% of SCT-eligible patients in all coun-
tries. Regardless of SCT status, lenalidomide/dexamethasone was the predominant 
second-line treatment (37%-48%) reported in France and Germany; in the UK, 
second-/later-line regimens were more varied, with both lenalidomide- and bort-
ezomib-based regimens being reported as common. Second-/later-line therapy dura-
tion was generally short, particularly in the UK where 75% of physicians reported 
a < 6-month duration. Disease progression was the top reason for second/later-
line discontinuation; other common reasons included toxicity and completion of 
planned therapy course. For high-risk patients, > 75% of physicians reported median 
survival of < 1 year from first relapse. ConClusions: The proportion of RRMM 
patients with high-risk disease in real-world settings (18%-24%) may exceed that 
reported in clinical trials (10%-15%). Second-/later-line therapy duration is typically 
short (< 6 months). Survival prospects for RRMM patients remain limited, particu-
larly for high-risk patients. Patient-level studies are needed to better characterize 
the unmet needs in RRMM signaled by our findings.
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objeCtives: Bleeding episodes pose significant economic and quality-of-life (QoL) 
burdens on persons with hemophilia. This study aims to identify socio-demo-
graphic and clinical characteristics associated with annual bleeding frequency 
(ABF). Methods: Between 2005-2007 and 2009-2012, the Hemophilia Utilization 
Group Studies Va and Vb, respectively, recruited hemophilia A or B patients from 
ten geographically diverse Hemophilia Treatment Centers in the United States. 
Adult patients or parents of children completed a baseline survey that collected 
information regarding socio-demographics, clinical characteristics, and treatment 
patterns. During the two-year observation period, bleeding episodes were collected 
through regular patient follow-ups. ABF was calculated as the annualized sum of 
patient-reported bleeding episodes. Two-year drug dispensing information was also 
recorded and annualized. Multivariable linear regressions were used to assess the 
association of patient variables with ABF. Results: Of 477 recruited patients, 317 
with complete baseline and utilization data and at least three months of patient 
follow-up were included. Among included patients, 49.8% were children, 39.7% used 
prophylaxis, and 63.1% had severe hemophilia. Variables significantly associated 
with ABF included 37 or older vs. 2-9 years of age (p= 0.03), married or with a partner 
(p= 0.03), hemophilia B (p= 0.09), mild/moderate hemophilia (p= 0.01), prophylaxis 
(p< 0.01), human immunodeficiency virus (HIV) (p< 0.01), hepatitis C virus (HCV) 
(p< 0.01), and annual factor usage per kilogram of body weight (p< 0.01). Among 
adults, age in years (p= 0.07), no insurance vs. public insurance (p= 0.04), mild/mod-
